Lilly Will Acquire Sleep Drug Company | Chemical & Engineering News
Volume 85 Issue 11 | p. 20 | Concentrates
Issue Date: March 12, 2007

Lilly Will Acquire Sleep Drug Company

Department: Business

Eli Lilly & Co. will acquire Hypnion, a small Lexington, Mass., neuroscience-based drug company focused on sleep disorders. Steven M. Paul, a Lilly executive vice president, says the purchase "provides Lilly with a broader and more substantive presence in the area of sleep disorder research." Hypnion announced in January that its small-molecule insomnia compound HY10275 had good results in a Phase II clinical trial. Lilly is developing its own insomnia treatment, pruvanserin.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment